TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Brief Summary: Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder. Early experience with varenicline indicates that it will be effective for smoking cessation in schizophrenia and in addition, has the potential to be therapeutic for cognitive dysfunction in this population. In addition, more data is needed to evaluate the safety, tolerability and effectiveness of Varenicline in people with bipolar disorder.

To assess this possibility, we will evaluate the safety and efficacy of 12 months of varenicline in schizophrenia or bipolar disorder patients who are able to quit smoking in the short term with this treatment. To do so, we will enroll 324 smokers with schizophrenia or bipolar disorder from 6 mental health clinics in Massachusetts, New Hampshire, Michigan and Minnesota into an open, 12-week smoking cessation program that includes varenicline added to weekly group cognitive behavioral therapy (CBT). Those who achieve at least 2 weeks of continuous abstinence during the last 2 weeks of the open intervention will be randomized to the relapse prevention phase: a 40-week, double blind, placebo-controlled trial of varenicline at the dose used to quit smoking added to a tapering CBT schedule. Participants will then discontinue study medications and behavioral treatment and enter a 3-month follow up phase.


Options:
A: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Randomized Phase: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Randomized Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Randomized Phase: Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Phase: Placebo
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking
Brief Summary: Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder. Early experience with varenicline indicates that it will be effective for smoking cessation in schizophrenia and in addition, has the potential to be therapeutic for cognitive dysfunction in this population. In addition, more data is needed to evaluate the safety, tolerability and effectiveness of Varenicline in people with bipolar disorder.

To assess this possibility, we will evaluate the safety and efficacy of 12 months of varenicline in schizophrenia or bipolar disorder patients who are able to quit smoking in the short term with this treatment. To do so, we will enroll 324 smokers with schizophrenia or bipolar disorder from 6 mental health clinics in Massachusetts, New Hampshire, Michigan and Minnesota into an open, 12-week smoking cessation program that includes varenicline added to weekly group cognitive behavioral therapy (CBT). Those who achieve at least 2 weeks of continuous abstinence during the last 2 weeks of the open intervention will be randomized to the relapse prevention phase: a 40-week, double blind, placebo-controlled trial of varenicline at the dose used to quit smoking added to a tapering CBT schedule. Participants will then discontinue study medications and behavioral treatment and enter a 3-month follow up phase.


Options:
A: Arm Label: Reduced Nicotine Content Cigarettes; Type: EXPERIMENTAL; Interventions: Drug: Reduced Nicotine Content Cigarettes | Arm Label: Usual Nicotine Content Cigarettes; Type: PLACEBO_COMPARATOR; Interventions: Drug: Usual Nicotine Content Cigarettes | Intervention Type: DRUG; Name: Reduced Nicotine Content Cigarettes; Assigned to Arm(s): Reduced Nicotine Content Cigarettes | Intervention Type: DRUG; Name: Usual Nicotine Content Cigarettes; Assigned to Arm(s): Usual Nicotine Content Cigarettes
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
D: Arm Label: Randomized Phase: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Randomized Phase: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Randomized Phase: Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Phase: Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Fenoldopam in Reducing the Need for Renal Replacement Therapy After Cardiac Surgery. A Randomized Controlled Study.
Brief Summary: Patients undergoing cardiac surgery could develop postoperative acute renal failure requiring renal replacement therapy.

Fenoldopam, already used for patients with hypertensive emergencies, could improve renal function in critically ill patients with or at risk for acute renal failure.


Options:
A: Arm Label: Rhythm control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amiodarone, Procedure: DC-cardioversion | Arm Label: Rate control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rate Control | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): Rhythm control | Intervention Type: PROCEDURE; Name: DC-cardioversion; Assigned to Arm(s): Rhythm control | Intervention Type: DRUG; Name: Rate Control; Assigned to Arm(s): Rate control
B: Arm Label: volatile anesthetics (desflurane, isoflurane, sevoflurane); Type: EXPERIMENTAL; Interventions: Drug: desflurane, isoflurane, sevoflurane | Arm Label: total intravenous anesthesia; Type: ACTIVE_COMPARATOR; Interventions: Drug: total intravenous anesthetics | Intervention Type: DRUG; Name: desflurane, isoflurane, sevoflurane; Assigned to Arm(s): volatile anesthetics (desflurane, isoflurane, sevoflurane) | Intervention Type: DRUG; Name: total intravenous anesthetics; Assigned to Arm(s): total intravenous anesthesia
C: Arm Label: Fenoldopam; Type: EXPERIMENTAL; Interventions: Drug: fenoldopam | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: fenoldopam; Assigned to Arm(s): Fenoldopam | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Embol-X Embolic Protection Device; Type: ACTIVE_COMPARATOR; Interventions: Device: Embol-X Embolic Protection Device | Arm Label: CardioGard Cannula; Type: ACTIVE_COMPARATOR; Interventions: Device: CardioGard Cannula | Arm Label: Standard Cannula; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Embol-X Embolic Protection Device; Assigned to Arm(s): Embol-X Embolic Protection Device | Intervention Type: DEVICE; Name: CardioGard Cannula; Assigned to Arm(s): CardioGard Cannula

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Levobupivacïne Into Post-analgesia : Randomized Monocentric Study Against Placebo
Brief Summary: The locoregional anaesthesia is increasingly important in surgical practice, often allowing to simplify per- and post-operative analgesia. caesarian occurs in 20 % of delivery leading to a longer hospitalization because of the pain resulting from the surgery. The Levobupivacaïne (Chirocaïne) administered through catheters placed in the caesarean scars, showed its efficiency in post-operative analgesia.

Method : realization of a double blind prospective randomized study, control versus placebo Purpose : to show that the local administration of a unique dose of analgesia reduce the post-operative pain with a little or non-invasive technique


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: chirocaine (Levobupivacaine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride | Intervention Type: DRUG; Name: chirocaine (Levobupivacaine); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sodium chloride; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Procedure: perioperative epidural catheter | Intervention Type: PROCEDURE; Name: perioperative epidural catheter; Assigned to Arm(s): 1, 2, 3, 4, 5
C: Arm Label: Group L; Type: EXPERIMENTAL; Interventions: Drug: Systemic intravenous lidocaine infusion | Arm Label: Group C; Type: PLACEBO_COMPARATOR; Interventions: Drug: normal saline infusion | Intervention Type: DRUG; Name: Systemic intravenous lidocaine infusion; Assigned to Arm(s): Group L | Intervention Type: DRUG; Name: normal saline infusion; Assigned to Arm(s): Group C
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: ketamine | Intervention Type: DRUG; Name: ketamine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Levobupivacïne Into Post-analgesia : Randomized Monocentric Study Against Placebo
Brief Summary: The locoregional anaesthesia is increasingly important in surgical practice, often allowing to simplify per- and post-operative analgesia. caesarian occurs in 20 % of delivery leading to a longer hospitalization because of the pain resulting from the surgery. The Levobupivacaïne (Chirocaïne) administered through catheters placed in the caesarean scars, showed its efficiency in post-operative analgesia.

Method : realization of a double blind prospective randomized study, control versus placebo Purpose : to show that the local administration of a unique dose of analgesia reduce the post-operative pain with a little or non-invasive technique


Options:
A: Arm Label: 0.25% Ropivicaine; Type: EXPERIMENTAL; Interventions: Drug: Ropivicaine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline placebo | Intervention Type: DRUG; Name: Saline placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ropivicaine; Assigned to Arm(s): 0.25% Ropivicaine
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lidocaine; Type: EXPERIMENTAL; Interventions: Drug: Lidocaine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Lidocaine
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: chirocaine (Levobupivacaine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride | Intervention Type: DRUG; Name: chirocaine (Levobupivacaine); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sodium chloride; Assigned to Arm(s): 2
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: ketamine | Intervention Type: DRUG; Name: ketamine; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controled Multicenter Trial Regarding the Appropriate Length of Postoperative Catheterization After Anterior Colporrhaphy for Repair of Cystocele
Brief Summary: Randomised controled multicenter trial about the appropriate length of postoperative catheterization after anterior colporrhaphy. Patients are included at the moment that they are planned for surgery and are allocated to one of the study arms after the operation in the recovery by a digital randomisation-procedure. 230 patients will be enrolled in the study and half of the patients will have a catheter during five days postoperatively and the other half will be catheterized only during two days. Main outcome measurements regards replacement of a catheter because of bladder retention and the occurence of cystitis.


Options:
A: Arm Label: 24 hour postop catheter removal; Type: EXPERIMENTAL; Interventions: Drug: Prazosin given 6 hours prior to catheter removal in the 24 hour group | Arm Label: 72 hour postoperative catheter removal; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Prazosin given 6 hours prior to catheter removal in the 24 hour group; Assigned to Arm(s): 24 hour postop catheter removal
B: Arm Label: Early removal group; Type: EXPERIMENTAL; Interventions: Procedure: Early removal group | Arm Label: Normal removal group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Normal removal group | Intervention Type: PROCEDURE; Name: Early removal group; Assigned to Arm(s): Early removal group | Intervention Type: PROCEDURE; Name: Normal removal group; Assigned to Arm(s): Normal removal group
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: postoperative catheterization | Arm Label: 2.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: postoperative catheterization | Intervention Type: PROCEDURE; Name: postoperative catheterization; Assigned to Arm(s): 1, 2.
D: Arm Label: Conventional Foley Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Fast Tract Foley care; Type: EXPERIMENTAL; Interventions: Other: Fast Track foley removal | Intervention Type: OTHER; Name: Fast Track foley removal; Assigned to Arm(s): Fast Tract Foley care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Double-blind, Active-controlled Parallel Group Efficacy and Safety Study of BI 1356 ( 5.0 mg, Administered Orally Once Daily) Compared to Glimepiride Over Two Years in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Metformin Therapy
Brief Summary: The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5.0 mg daily) compared to glimepiride given for 104 weeks as add-on therapy to preferably \> 1500 mg metformin in patients with type 2 diabetes mellitus with insufficient glycaemic control


Options:
A: Arm Label: BI 1356 5mg, once daily; Type: EXPERIMENTAL; Interventions: Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, Drug: BI 1356 | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo identical to BI 1356 5mg, Drug: Glimepiride | Intervention Type: DRUG; Name: Placebo identical to BI 1356 5mg; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride
B: Arm Label: 1.5 mg Dulaglutide; Type: EXPERIMENTAL; Interventions: Drug: Dulaglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dulaglutide; Assigned to Arm(s): 1.5 mg Dulaglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 low dose, Drug: Placebo BI 10773 high dose | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773 high dose, Drug: Placebo BI 10773 low dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo BI 10773 high dose, Drug: Placebo BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773 low dose; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773 high dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo BI 10773 low dose; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo BI 10773 high dose; Assigned to Arm(s): BI 10773 low dose
D: Arm Label: Linagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International, Multi-center, Randomized, Double Blind Study to Compare the Overall Mortality in Acutely Ill Medical Patients Treated With Enoxaparin Versus Placebo in Addition to Graduated Elastic Stockings
Brief Summary: The primary objective:

* To demonstrate in patients hospitalized for an acute medical illness that enoxaparin with Graduated Elastic Stockings is superior to enoxaparin-placebo with Graduated Elastic Stockings on overall mortality at day 30 after randomization.

The secondary objective:

* To compare, in patients hospitalized for an acute medical illness, enoxaparin with Graduated Elastic Stockings versus enoxaparin placebo with Graduated Elastic Stockings on overall mortality at day 90 after randomization.
* To evaluate the safety of enoxaparin VTE prophylaxis in patients hospitalized for acute medical illness with respect to major hemorrhage, total bleedings, heparin induced thrombocytopenia, adverse events and serious adverse events .


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2
B: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Enoxaparin placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Feeding Study to Examine the Effect of Glycemic Load and Obesity on Cancer Biomarkers
Brief Summary: This study is designed to investigate associations of low- and high-glycemic load diets with biomarkers of hyperglycemia, hyperinsulinemia and inflammation, potential biomarkers for cancer risk.


Options:
A: Intervention Type: BEHAVIORAL; Name: Low glycemic index diet; Assigned to Arm(s): N/A
B: Arm Label: LGI; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Low glycemic index diet | Arm Label: HGI; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High glycemic index diet | Arm Label: HB; Type: EXPERIMENTAL; Interventions: Other: Home-based exercise intervention | Arm Label: CONTROL; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-exercisers | Intervention Type: DIETARY_SUPPLEMENT; Name: Low glycemic index diet; Assigned to Arm(s): LGI | Intervention Type: DIETARY_SUPPLEMENT; Name: High glycemic index diet; Assigned to Arm(s): HGI | Intervention Type: OTHER; Name: Home-based exercise intervention; Assigned to Arm(s): HB | Intervention Type: OTHER; Name: Non-exercisers; Assigned to Arm(s): CONTROL
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: High or low Glycemic Index and high or low Protein Diet | Intervention Type: BEHAVIORAL; Name: High or low Glycemic Index and high or low Protein Diet; Assigned to Arm(s): 1, 2, 3, 4, 5
D: Arm Label: 1; Type: OTHER; Interventions: Other: Low Glycemic Load Diet, Other: High Glycemic Load Diet | Arm Label: 2; Type: OTHER; Interventions: Other: Low Glycemic Load Diet, Other: High Glycemic Load Diet | Intervention Type: OTHER; Name: Low Glycemic Load Diet; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: High Glycemic Load Diet; Assigned to Arm(s): 1, 2

Answer: D